Roche lets money do the talking with hostile $5.7bn bid after Illumina negotiations fail
This article was originally published in Scrip
Executive Summary
Roche has made a $5.7 billion hostile takeover bid for gene sequencing market leader Illumina, in an effort to consolidate its number-one position in the diagnostics market and boost its presence in the genetic testing sector.